WO2014113616A1 - Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline - Google Patents
Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline Download PDFInfo
- Publication number
- WO2014113616A1 WO2014113616A1 PCT/US2014/011948 US2014011948W WO2014113616A1 WO 2014113616 A1 WO2014113616 A1 WO 2014113616A1 US 2014011948 W US2014011948 W US 2014011948W WO 2014113616 A1 WO2014113616 A1 WO 2014113616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- give
- methoxy
- yloxy
- nitro
- Prior art date
Links
- 0 CC*C(c1c(ccc(Oc2c(cc(c(OCC3(CC3)NC(OC/C3=C\*(*)/C=C/C(C)(*)/C=C3)=O)c3)OC)c3ncc2)c2)c2ccc1)=O Chemical compound CC*C(c1c(ccc(Oc2c(cc(c(OCC3(CC3)NC(OC/C3=C\*(*)/C=C/C(C)(*)/C=C3)=O)c3)OC)c3ncc2)c2)c2ccc1)=O 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the present invention relates a new process to synthesize 6-(7-((l-aminocyclo-propyl)- methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide (AL3810) by deprotection of substituted benzyl 1 -((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)- methyl)cyclopropylcarbamate (Formula I) under a diluted or weak acidic condition.
- a stable crystalline form of 6-(7-((l-aminocyclo-propyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N- methyl- 1 -naphthamide has also been prepared.
- This compound has been structurally disclosed in WO20081 12408 as an agiogenesis inhibitor with few preparation methods.
- a new process has been disclosed in WO2010105761 with the removal of use of sodium azide. Both above disclosed processes have involved a deprotection of benzyl carbmate protected precursor by HBr/Acetic acid solution that is a strong, fuming and high corrosive acidic condition. No crystalline form has been disclosed.
- EtOH ethanol
- MeOH methanol
- IPA isopropanol
- EtOAc ethyl acetate
- RT room temperature
- DIPEA diisopropylethylamine
- DCM Dichloromethane
- DMF NN-dimethylformamide
- NMP 1 -Methyl-2-pyrrolidinone
- ACN acetonitrile
- DEAD Diethyl azodicarboxylate
- DIAD Diisopro- pyl azodicarboxylate
- CDI ⁇ , -Carbonyldiimidazole
- MeNH 2 .HCl methylamine hydrochloride
- TSA.H20 4-toluensulfonic acid monohydrate
- DMAP 4-N,N-dimethylaminopyridine
- MsCl methanesulfonyl chloride
- THF tetrahydr
- halogen as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. such as fluoro and chloro.
- halogeno-Ci-Cealkyl includes 1 to 6 halogen substituted alkyl, such as trifluoromethyl.
- Ci-Cealkyl includes 1 to 6 saturated monovalent hydrocarbon radicals having straight or branched moieties, including, but not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec -butyl, tert-butyl, and the like.
- Ci-Cealkoxy includes -OCi-Cealkyl groups wherein Ci-Cealkyl is as defined above, such as methoxy and ethoxy.
- cyano as used herein, unless otherwise indicated, includes -CHST.
- nitro as used herein, unless otherwise indicated, includes -N0 2 .
- the present invention relates to a process for preparing 6-(7-((l-aminocyclopropyl)- methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide (AL3810) by deprotection of substituted benzyl 1 -((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)- methyl)cyclopropylcarbamate Formula I under a diluted or weak acidic condition according to Process A.
- P i is selected from H, halogen, halogeno-Ci-C 6 alkyl, Ci-C 6 alkyl, Ci-C 6 alkoxy, cyano or nitro; Pv 2 is selected from Ci-C 6 alkoxy, or nitro.
- the present invention relates to the compound of Formula I.
- the present invention relates to the methods of preparing a compound having the Formula I.
- the present invention also relates to various intermediates useful in the preparation of a compound having the Formula I, and the present invention further relates to the methods of preparing such intermediates.
- the present invention relates to the methods of preparing a crystalline form of 6-(7-((l- aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- l -naphthamide.
- Fig 1 provides a HI nuclear magnetic resonance (NMR) graph of a crystalline form of 6- (7-((l -aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide.
- Fig 2 provides a differential scanning calorimetric (DSC) graph of a crystalline form of 6-(7-((l -aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide.
- DSC differential scanning calorimetric
- Fig 3 provides a thermogravimetric analysis (TGA) graph of a crystalline form of 6-(7- (( 1 -aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide.
- Fig 4 provides an X-ray powder diffraction (XRPD) graph of a crystalline form of 6-(7- (( 1 -aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide.
- XRPD X-ray powder diffraction
- the present invention relates to a process for preparing 6-(7-((l-aminocyclo-propyl)- methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide (AL3810) by deprotection of substituted benzyl 1 -((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)- methyl)cyclopropylcarbamate Formula I under a diluted or weak acidic condition according to above Process A.
- Ri is selected from H, halogen, halogeno-Ci-Cealkyl, Ci-Cealkyl, Ci-Cealkoxy, cyano or nitro; preferably selected from H, Ci-Cealkoxy, or nitro;
- R 2 is selected from Ci-Cealkoxy, or nitro; preferably R 2 is methoxy.
- a diluted or weak acidic condition is selected from 5-50% TFA in CH 2 C1 2 or CH 3 CN, 10% HC1 in ethanol, 4NHC1 in dioxane, HCOOH in CH 3 CN or p-toluenesulfonic acid monohydrate in CH 3 CN; preferably the acid is 10% TFA in CH 2 C1 2.
- the total volume ratio of solvent to reactant is from 2 to 20 folds by weight.
- the reaction temperature is selected from 0 to 80°C and the reaction time is selected from 0.5 to 24 hours.
- a preferred procedure is shown in Scheme I.
- the present invention relates to a process for preparing 6-(7-((l-aminocyclo-propyl)- methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide (AL3810) by deprotection of 4- methoxybenzyl l-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)-quinolin-7-yloxy)- methyl)cyclopropylcarbamate Formula II according to Process B.
- the present invention relates to the compound of Formula II.
- the present invention relates to the methods of preparing a compound having the Formula II.
- the present invention also relates to various intermediates useful in the preparation of a compound having the Formula II, and the present invention further relates to the methods of preparing such intermediates.
- Process B of the invention comprises preparing AL3810, a preferred procedure is shown in Scheme II via:
- the present invention relates to a compound of Formula I or Formula II and the method preparing Formula I or Formula II according to Process C.
- Process C
- Ri is selected from H, halogen, halogeno-Ci-Cealkyl, Ci-Cealkyl, Ci-Cealkoxy, cyano or nitro;
- R 2 is selected from Ci-C 6 alkoxy, or nitro.
- Process C of the invention comprises preparing Formula I, a preferred procedure is shown in Scheme III via the reaction between formula 14 and Formula VI using a base, such as: Na 2 C0 3 , Cs 2 C0 3 or K 2 C0 3 , or between formula 14 and Formula V using a base, such as: Na 2 C0 3 , Cs 2 C0 3 or K 2 C0 3 , and KI or Nal to give Formula I, preferably the reaction is at a heated condition, such as 60- 120 °C in acetone, DMF or NMP.
- Formula 14 can be prepared by following steps:
- Formula VI or Formula V can be prepared by following steps:
- Process C of the invention comprises preparing Formula II, a preferred procedure is shown in Scheme IV via the reaction between formula 14 and formula 15f using a base, such as: Na 2 C0 3 , CS 2 CO 3 or K 2 CO 3 , or between formula 14 and formula 15d using a base, such as: Na 2 C03, CS 2 CO 3 or K 2 CO 3 , and KI or Nal at a heated condition, such as at 60- 120 °C of one pot reaction in acetone, DMF or NMP to give Formula II.
- a base such as: Na 2 C0 3 , CS 2 CO 3 or K 2 CO 3
- a base such as: Na 2 C03, CS 2 CO 3 or K 2 CO 3
- KI or Nal at a heated condition, such as at 60- 120 °C of one pot reaction in acetone, DMF or NMP to give Formula II.
- the present invention relates to the compound of Formula I and the method preparing Formula I according to Process D.
- Process D of the invention comprises preparing Formula I, a preferred procedure is shown in Scheme V via acylazide formula 17 reacting with Ri, R 2 substituted benzyl alcohol in a heated condition, preferably toulene or dioxane refluxing condition.
- Formula 17 can be prepared by reacting formula 16 with ethyl chloroformate at 0°C in DMF or THF at the presence of TEA or DIPEA to form a mixed anhydride that can be reacted with NaN 3 /DMF solution at similar temperature.
- Formula 16 can be prepared according to WO20081 12408.
- the present invention relates to the compound of Formula I and the method preparing Formula I according to Process E.
- Process E
- Ri is selected from H, halogen, halogeno-Ci-Cealkyl, Ci-Cealkyl, Ci-Cealkoxy, cyano or nitro;
- R 2 is selected from Ci-C 6 alkoxy, or nitro.
- Process E of the invention comprises preparing Formula I, a preferred procedure is shown in Scheme VI via acylation of Formula VIII with methylamine hydrochloride with heat pre- activation of formula VIII at the presence of CDI gives Formula I, preferably the reaction is carried out in DMF or dioxane for 2-8 hours withl .5-4 eq CDI at 50- 120 °C.
- Formula VII can be similarly prepared by reacting formula 19 with Formula VI with a base, such as: Na 2 C0 3 , CS 2 CO 3 or K 2 CO 3 , or with Formula V in one pot KI or Nal with a base, such as: Na 2 C0 3 , Cs 2 C0 3 or K 2 CO 3 , as described in Scheme III.
- Formula VIII can be prepared by hydrolysis of Formula VII under a strong basic condition, such as a mixture of an aqueous NaOH solution and EtOH.
- Formula 19 can be prepared according to WO20081 12408 from formula 18.
- the present invention relates to the compound of Formula I or Formula II and the method preparing Formula I or Formula II according to Process F.
- Process F
- Ri is selected from H, halogen, halogeno-Ci-Cealkyl, Ci-Cealkyl, Ci-Cealkoxy, cyano or nitro;
- R 2 is selected from Ci-C 6 alkoxy, or nitro.
- Process F of the invention comprises preparing Formula I, a preferred procedure is shown in Scheme VII via:
- Formula IX can be prepared by reacting Formula IV with formula 21 under Mitusnobu reaction condition in THF at 0-40°C for 2-24 hours by use of Mitusnobu reagents, such as: DEAD or DIAD at the presence of a Mitsunobu ligand, such as triphenylphosphine.
- Mitusnobu reagents such as: DEAD or DIAD
- a Mitsunobu ligand such as triphenylphosphine.
- Formula 21 can be prepared by deprotection of formula 20 with TFA at 60-100 °C for 0.5-8 hours to give a TFA salt that can be neutralized by aqueous NaHC03 solution, and then filtered off.
- Process F of the invention comprises preparing Formula II, a preferred procedure is shown in Scheme VIII via:
- Formula 21b can be prepared by reacting formula 15c with formula 21 under Mitusnobu reaction condition in THF at 0-40°C for 2-24 hours with use of Mitsunobu reagents, such as: DEAD or DIAD, at the presence of a Mitsunobu ligand, such as triphenylphosphine.
- Mitsunobu reagents such as: DEAD or DIAD
- the present invention relates to the methods of preparing a crystalline form of 6-(7-((l- aminocyclopropyl)-methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl- 1 -naphthamide (AL3810) by recrystallizing the crude product from isopropanol to give a stable crystalline form.
- the crude product was dissolved at refluxing condition for 15 minutes to 3 hours in isopropanol with certain amount of active carbon.
- the reaction was filtered at hot condition and cooled to room temperature (optionally cooled at 4°C) for 4 to 48 hours.
- the precipitate was filtered and dried under high vacuum at 25°C-80°C to give a stable crystalline form with melting point at 185°C- 205 C.
- the crystalline form has no observable endotherm from about 40 C to about 185 C as determined by DSC. It has observable endotherm from about 185°C to about 210°C as determined by DSC.
- the crystalline form has a TGA themogram that doesn't exhibit significant weight loss until at 210°C to 250°C to indicate that it is an unsolvated material.
- the crystalline form has 20- 40 characteristic peaks on XRPD graph.
- Example 2 The crude product from Example 1 (105 g) was mixed with isopropanol (2.5 L) and active carbon (5 g), the mixture was heated to reflux for 0.5 hour to dissolve all crude product followed by filtration while it was hot, then the filtrate was refluxed again for 10 minutes and it was cooled to room temperature overnight under a slow stirring condition. The precipitate was filtered and washed with ethyl ether (500 ml x 2), further dried under high vacuum at 80°C to give the pure product (85 g) with melting point at 192°C- 196°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015127211A RU2015127211A (en) | 2013-01-18 | 2014-01-17 | METHOD FOR PRODUCING ANTITUMOR AGENT 6- (7 - ((1-AMINOCYCLOPROPYL) METHOXY) -6-METOXYCHINOLIN-4-ILOXY) -N-METHYL-1-NAPHTHAMIDE AND ITS CRYSTAL STRUCTURE |
BR112015017100A BR112015017100A2 (en) | 2013-01-18 | 2014-01-17 | Process for the preparation of the antitumor agent 6- (7 - ((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -n-methyl-1-naphtamide and its crystalline lens |
MA38274A MA38274A1 (en) | 2013-01-18 | 2014-01-17 | A process for preparing an antitumor agent, 6- (7 - ((1-amino-cyclo-propyl) -methoxy) -6-methoxyquinolin-4-yloxy) -n-methyl-1-naphthamide, and its crystalline form |
KR1020157021964A KR102275034B1 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
SG11201505389WA SG11201505389WA (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
US14/760,549 US9783498B2 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline |
CN201480005301.1A CN104936946A (en) | 2013-01-18 | 2014-01-17 | Process for preparing anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
MX2015008543A MX2015008543A (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopro pyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline. |
CA2896898A CA2896898A1 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
EA201591205A EA201591205A1 (en) | 2013-01-18 | 2014-01-17 | WAY OF OBTAINING ANTITUMOR AGENT 6- (7 - ((1-AMINOCYCLOPROPYL) -METOXI) -6-METHOXYCHINOLIN-4-ILOXI) -N-METHYL-1-NAFTHAMIDE AND ITS CRYSTAL STRUCTURE |
JP2015553837A JP2016506917A (en) | 2013-01-18 | 2014-01-17 | Process for preparing antitumor agent 6- (7-((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide and crystals thereof |
AU2014207482A AU2014207482A1 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and its crystalline |
EP14740190.5A EP2945931A4 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
IL239877A IL239877B (en) | 2013-01-18 | 2015-07-09 | Process for preparing the crystalline form of the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide |
ZA2015/05043A ZA201505043B (en) | 2013-01-18 | 2015-07-14 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
PH12015501571A PH12015501571A1 (en) | 2013-01-18 | 2015-07-15 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
HK16101503.0A HK1213563A1 (en) | 2013-01-18 | 2016-02-11 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline 6-(7-((1-))-6--4-)-n- -1- |
HK16105284.6A HK1217328A1 (en) | 2013-01-18 | 2016-05-10 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline 6-(7-((1-))-6--4-)-n- -1- |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361754516P | 2013-01-18 | 2013-01-18 | |
US61/754,516 | 2013-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014113616A1 true WO2014113616A1 (en) | 2014-07-24 |
Family
ID=51210076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/011948 WO2014113616A1 (en) | 2013-01-18 | 2014-01-17 | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline |
Country Status (18)
Country | Link |
---|---|
US (1) | US9783498B2 (en) |
EP (1) | EP2945931A4 (en) |
JP (1) | JP2016506917A (en) |
KR (1) | KR102275034B1 (en) |
CN (2) | CN111454206A (en) |
AU (1) | AU2014207482A1 (en) |
BR (1) | BR112015017100A2 (en) |
CA (1) | CA2896898A1 (en) |
EA (1) | EA201591205A1 (en) |
HK (2) | HK1213563A1 (en) |
IL (1) | IL239877B (en) |
MA (1) | MA38274A1 (en) |
MX (1) | MX2015008543A (en) |
PH (1) | PH12015501571A1 (en) |
RU (1) | RU2015127211A (en) |
SG (1) | SG11201505389WA (en) |
WO (1) | WO2014113616A1 (en) |
ZA (1) | ZA201505043B (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
US9968597B2 (en) | 2014-06-06 | 2018-05-15 | Advenchen Laboratories Nanjing Ltd | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same |
US10112945B2 (en) | 2014-07-14 | 2018-10-30 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as PI3K, mTOR inhibitors |
US10251876B2 (en) | 2014-06-06 | 2019-04-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for treating tumour, pharmaceutical composition and medicinal kit |
US10307412B2 (en) | 2014-12-09 | 2019-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative against non-small cell lung cancer |
US10730878B2 (en) | 2015-07-11 | 2020-08-04 | Advenchen Pharmaceuticals, LLC | Fused quinoline compounds as PI3K/mTOR inhibitors |
US10736887B2 (en) | 2016-04-15 | 2020-08-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treating gastric cancer |
US11279676B2 (en) | 2018-03-02 | 2022-03-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110483392A (en) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | Synthesize the method and synthetic intermediate of the quinoline -7- base oxygroup methylcyclopropyl groups amine derivative of N-protected |
CN110483393A (en) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | The vertical crystal form for Buddhist nun of moral |
CN115160221A (en) * | 2022-07-26 | 2022-10-11 | 上海歆贻医药科技有限公司 | Delitinib crystal form compound and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112408A1 (en) | 2007-03-14 | 2008-09-18 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
WO2010105761A1 (en) | 2009-03-16 | 2010-09-23 | Eos Ethical Oncology Science S.P.A. In Abbreviated Form Eos S.P.A. | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
KR101909433B1 (en) * | 2011-12-02 | 2018-10-18 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | Agent for reducing adverse side effects of kinase inhibitor |
US20150258120A1 (en) * | 2012-11-08 | 2015-09-17 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
-
2014
- 2014-01-17 WO PCT/US2014/011948 patent/WO2014113616A1/en active Application Filing
- 2014-01-17 KR KR1020157021964A patent/KR102275034B1/en active IP Right Grant
- 2014-01-17 CN CN202010295470.0A patent/CN111454206A/en active Pending
- 2014-01-17 EA EA201591205A patent/EA201591205A1/en unknown
- 2014-01-17 RU RU2015127211A patent/RU2015127211A/en unknown
- 2014-01-17 MX MX2015008543A patent/MX2015008543A/en unknown
- 2014-01-17 SG SG11201505389WA patent/SG11201505389WA/en unknown
- 2014-01-17 CA CA2896898A patent/CA2896898A1/en active Pending
- 2014-01-17 JP JP2015553837A patent/JP2016506917A/en active Pending
- 2014-01-17 BR BR112015017100A patent/BR112015017100A2/en not_active IP Right Cessation
- 2014-01-17 EP EP14740190.5A patent/EP2945931A4/en not_active Withdrawn
- 2014-01-17 MA MA38274A patent/MA38274A1/en unknown
- 2014-01-17 AU AU2014207482A patent/AU2014207482A1/en not_active Abandoned
- 2014-01-17 CN CN201480005301.1A patent/CN104936946A/en active Pending
- 2014-01-17 US US14/760,549 patent/US9783498B2/en active Active
-
2015
- 2015-07-09 IL IL239877A patent/IL239877B/en not_active IP Right Cessation
- 2015-07-14 ZA ZA2015/05043A patent/ZA201505043B/en unknown
- 2015-07-15 PH PH12015501571A patent/PH12015501571A1/en unknown
-
2016
- 2016-02-11 HK HK16101503.0A patent/HK1213563A1/en unknown
- 2016-05-10 HK HK16105284.6A patent/HK1217328A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112408A1 (en) | 2007-03-14 | 2008-09-18 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
WO2010105761A1 (en) | 2009-03-16 | 2010-09-23 | Eos Ethical Oncology Science S.P.A. In Abbreviated Form Eos S.P.A. | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof |
Non-Patent Citations (6)
Title |
---|
BELLO, E. ET AL.: "E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models", CANCER RES., vol. 71, no. 4, 2011, pages 1396 - 1405, XP002716768 * |
CANCER RES, vol. 71, no. 4, 15 February 2011 (2011-02-15), pages 1396 - 1405 |
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 16, 10 October 2012 (2012-10-10), pages 2321 - 2330 |
SALA, F. ET AL.: "Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in clinical pharmacokinetic study", J. MASS. SPECTROM., vol. 46, 2011, pages 1039 - 1045, XP055277018 * |
See also references of EP2945931A4 |
ZHOU, Y. ET AL.: "AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR", J. CELL . MOL. MED., vol. 16, no. 10, 2012, pages 2321 - 2330, XP055276894 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10183017B2 (en) | 2014-06-06 | 2019-01-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same |
US9968597B2 (en) | 2014-06-06 | 2018-05-15 | Advenchen Laboratories Nanjing Ltd | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same |
US10251876B2 (en) | 2014-06-06 | 2019-04-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Method for treating tumour, pharmaceutical composition and medicinal kit |
US10112945B2 (en) | 2014-07-14 | 2018-10-30 | Advenchen Pharmaceuticals, Nanjing Ltd. | Fused quinoline compunds as PI3K, mTOR inhibitors |
US10888559B2 (en) | 2014-12-09 | 2021-01-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivatives for non-small cell lung cancer |
US10307412B2 (en) | 2014-12-09 | 2019-06-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative against non-small cell lung cancer |
JP2018515482A (en) * | 2015-05-04 | 2018-06-14 | アドヴェンチェン ファーマスーティカルズ,エルエルシー | Anticancer agent 1-((4- (4-fluoro-2-methyl-1H-indole-5-yloxy) -6-methoxyquinoline-7-yloxy) methyl) cyclopropanamine, its crystalline form and its salt Preparation method |
US10100034B2 (en) | 2015-05-04 | 2018-10-16 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
US10544125B2 (en) | 2015-05-04 | 2020-01-28 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
KR20180014716A (en) * | 2015-05-04 | 2018-02-09 | 어드밴첸 파마수티컬스, 엘엘씨 | (4-fluoro-2-methyl-1H-indol-5-yloxy) -6-methoxyquinolin-7-yloxy) methyl) cyclopropanamine, its crystalline form and its salt Manufacturing method |
KR102613409B1 (en) | 2015-05-04 | 2023-12-14 | 어드밴첸 파마수티컬스, 엘엘씨 | l-((4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and salts thereof, which are anticancer drugs Manufacturing method |
US10730878B2 (en) | 2015-07-11 | 2020-08-04 | Advenchen Pharmaceuticals, LLC | Fused quinoline compounds as PI3K/mTOR inhibitors |
US10736887B2 (en) | 2016-04-15 | 2020-08-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treating gastric cancer |
US11279676B2 (en) | 2018-03-02 | 2022-03-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline of compound as c-Met kinase inhibitor and preparation method therefor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104936946A (en) | 2015-09-23 |
MX2015008543A (en) | 2015-11-16 |
US9783498B2 (en) | 2017-10-10 |
KR102275034B1 (en) | 2021-07-12 |
EA201591205A1 (en) | 2015-12-30 |
IL239877B (en) | 2018-07-31 |
PH12015501571A1 (en) | 2015-10-05 |
SG11201505389WA (en) | 2015-08-28 |
JP2016506917A (en) | 2016-03-07 |
US20150353496A1 (en) | 2015-12-10 |
HK1213563A1 (en) | 2016-07-08 |
BR112015017100A2 (en) | 2017-07-11 |
MA38274A1 (en) | 2017-02-28 |
IL239877A0 (en) | 2015-08-31 |
HK1217328A1 (en) | 2017-01-06 |
CA2896898A1 (en) | 2014-07-24 |
EP2945931A4 (en) | 2016-10-12 |
EP2945931A1 (en) | 2015-11-25 |
CN111454206A (en) | 2020-07-28 |
ZA201505043B (en) | 2017-11-29 |
AU2014207482A1 (en) | 2015-08-13 |
RU2015127211A (en) | 2017-03-03 |
KR20150108871A (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014113616A1 (en) | Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline | |
US10822305B2 (en) | Process for the preparation of 4-(4-amino-3-fluorophenoxy)-N-methylpyyridine-2-carboxamide | |
US9340508B2 (en) | Process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | |
CA2581835C (en) | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide | |
CA2698245C (en) | Process and intermediates for preparing integrase inhibitors | |
AU2020267299B2 (en) | Methods of making protein deacetylase inhibitors | |
EP3186229A1 (en) | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine | |
CN114773352B (en) | Process for preparing substituted nicotinamides | |
RU2440978C2 (en) | Method of producing 1-(3, 4-dichlorobenzyl)-5-octyl biguanide or salt thereof | |
CN114805314A (en) | Synthesis method of Ensaitevir | |
CA2584789C (en) | Method for the preparation of aripiprazole, and corresponding intermediates and their preparation | |
CN106008559B (en) | Synthesis process of substituted pyridopyrimidine compounds | |
CN117304179A (en) | Preparation process of Jactinib dihydrochloride monohydrate | |
CN113999200A (en) | Synthetic method of thiodiazaspiro compound, intermediate and synthetic method thereof | |
CN116410125A (en) | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | |
CN115925713A (en) | Diazacyclocycle compound intermediate and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14740190 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015553837 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2896898 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/008543 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 239877 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14760549 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: P912/2015 Country of ref document: AE Ref document number: 38274 Country of ref document: MA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591205 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015017100 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014740190 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201504798 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2014207482 Country of ref document: AU Date of ref document: 20140117 Kind code of ref document: A Ref document number: 20157021964 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201507420 Country of ref document: UA Ref document number: 13911 Country of ref document: GE |
|
ENP | Entry into the national phase |
Ref document number: 2015127211 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015017100 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150716 |